EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular alterations of driver genes in non-small cell lung cancer

Anna Grodzka, Agnieszka Knopik-Skrocka, Katarzyna Kowalska, Pawel Kurzawa, Monika Krzyzaniak, Katarzyna Stencel, Maciej Bryl

EXCLI Journal · 11.05.2023 · 22 · 415-432

DOI: 10.17179/excli2023-6122 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 11.05.2023. Verfasst von Anna Grodzka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Faculty of Biology, Adam Mickiewicz University of Poznan, Poland. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the leading cause of cancer death all over the world. The majority (80-85 %) of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Within NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the most often recognized. The histological and immunohistochemical examination of NSCLC is a basic diagnostic tool, but insufficient for comprehensive therapeutic decisions. In some NSCLC patients, mainly adenocarcinoma, molecular alterations in driver genes, like EGFR, KRAS, HER2, ALK, MET, BRAF, RET, ROS1, and NTRK are recognized. The frequency of some of those changes is different depending on race, and between smokers and non-smokers. The molecular diagnostics of NSCLC using modern methods, like next-generation sequencing, is essential in estimating targeted, personalized therapy. In recent years, a breakthrough in understanding the importance of molecular studies for the precise treatment of NSCLC has been observed. Many new drugs were approved, including tyrosine kinase and immune checkpoint inhibitors. Clinical trials testing novel molecules like miRNAs and trials with CAR-T cells (chimeric antigen receptor – T cells) dedicated to NSCLC patients are ongoing.

Schlagwörter

Stichwörter der Autor:innen

driver genesmolecular alterationsnon-small cell lung cancertargeted therapies

Autor:innen und Institutionen

  • Department of Cell Biology, Faculty of Biology, Adam Mickiewicz University of Poznan, Poland.
  • Department of Oncological Pathology, University Clinical Hospital in Poznan, Poznan University of Medical Sciences, Poland.
  • Department of Clinical Pathology and Immunology, Poznan University of Medical Sciences, Poland.
  • Department of Clinical Oncology with the Subdepartment of Diurnal Chemotherapy, E. J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Poznan, Poland.

Zitieren

APA

Grodzka, A., Knopik-Skrocka, A., Kowalska, K., Kurzawa, P., Krzyzaniak, M., Stencel, K., & Bryl, M. (2023). Molecular alterations of driver genes in non-small cell lung cancer. EXCLI Journal, 22, 415-432. https://doi.org/10.17179/excli2023-6122

Vancouver

Grodzka A, Knopik-Skrocka A, Kowalska K, Kurzawa P, Krzyzaniak M, Stencel K, et al. Molecular alterations of driver genes in non-small cell lung cancer. EXCLI Journal. 2023;22:415-432. doi:10.17179/excli2023-6122

BibTeX
@article{Grodzka2023,
  author = {Grodzka, Anna and Knopik-Skrocka, Agnieszka and Kowalska, Katarzyna and Kurzawa, Pawel and Krzyzaniak, Monika and Stencel, Katarzyna and Bryl, Maciej},
  title = {Molecular alterations of driver genes in non-small cell lung cancer},
  journal = {EXCLI Journal},
  year = {2023},
  volume = {22},
  pages = {415--432},
  doi = {10.17179/excli2023-6122}
}
Kostenlos starten →